News

TipRanks on MSN15h
GSK’s Promising Study on Belimumab for Lung Disease: What Investors Need to Know
GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
Infectious Disease Advisor4d
Initiating Belimumab Before Immunosuppressants May Reduce SLE Flares
Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.
TipRanks on MSN2d
GSK’s Promising Study on Belimumab for Systemic Sclerosis Lung Disease
GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
Renal & Urology News3d
BCMA CAR-T Cell Therapy Induces Remission in Refractory Lupus Nephritis
In a small trial, CAR T-cells were infused following lymphodepletion therapy in patients with refractory lupus nephritis.
Kepler Capital Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
In a report released on July 30, Nicolas Pauillac from Kepler Capital maintained a Hold rating on GlaxoSmithKline, with a price target of p1,500.00. The company’s shares closed yesterday at p1,418.00.